Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
See Our Latest Updates
See how you can join the team
Where we are going to be
− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent since company’s 2018 acquisition − BURLINGTON, Mass. and OXFORD, UK, March 17, 2020...
Read More ›− ASCO 2020 Genitourinary Cancers Symposium and Radiation Oncology Summit: ACRO 2020 − BURLINGTON, Mass. and OXFORD, UK, February 11, 2020 – Blue Earth Diagnostics, a Bracco company focused...
Read More ›− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in men with recurrent prostate cancer − BURLINGTON, Mass. and OXFORD, UK, September 16, 2019...
Read More ›BURLINGTON, Mass. and OXFORD, UK, September 10, 2019 – Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations at the 2019 American Society...
Read More ›